Cargando…
Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation
BACKGROUND: The optimal therapy of patients with acute subsegmental pulmonary embolism (PE) is controversial. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of symptomatic PE recurrences during anticoagulation in patients with subsegmental,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845079/ https://www.ncbi.nlm.nih.gov/pubmed/33537541 http://dx.doi.org/10.1002/rth2.12446 |
_version_ | 1783644484305682432 |
---|---|
author | Fernández‐Capitán, Carmen Rodriguez Cobo, Ana Jiménez, David Madridano, Olga Ciammaichella, Maurizio Usandizaga, Esther Otero, Remedios Di Micco, Pierpaolo Moustafa, Farès Monreal, Manuel |
author_facet | Fernández‐Capitán, Carmen Rodriguez Cobo, Ana Jiménez, David Madridano, Olga Ciammaichella, Maurizio Usandizaga, Esther Otero, Remedios Di Micco, Pierpaolo Moustafa, Farès Monreal, Manuel |
author_sort | Fernández‐Capitán, Carmen |
collection | PubMed |
description | BACKGROUND: The optimal therapy of patients with acute subsegmental pulmonary embolism (PE) is controversial. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of symptomatic PE recurrences during anticoagulation in patients with subsegmental, segmental, or more central PEs. RESULTS: Among 15 963 patients with a first episode of symptomatic PE, 834 (5.2%) had subsegmental PE, 3797 (24%) segmental, and 11 332 (71%) more central PE. Most patients in all subgroups received initial therapy with low‐molecular‐weight heparin, and then most switched to vitamin K antagonists. Median duration of therapy was 179, 185, and 204 days, respectively. During anticoagulation, 183 patients developed PE recurrences, 131 developed deep vein thrombosis (DVT), 543 bled, and 1718 died (fatal PE, 135). The rate of PE recurrences was twofold higher in patients with subsegmental PE than in those with segmental (hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.16‐3.85) or more central PE (HR, 1.89; 95% CI, 1.12‐3.13). On multivariable analysis, patients with subsegmental PE had a higher risk for PE recurrences than those with central PE (adjusted HR, 1.75; 95% CI, 1.02‐3.03). After stratifying patients with subsegmental PE according to ultrasound imaging in the lower limbs, the rate of PE recurrences was similar in patients with DVT, in patients without DVT, and in those with no ultrasound imaging. CONCLUSIONS: Our study reveals that the risk for PE recurrences in patients with segmental PE is not lower than in those with more central PE, thus suggesting that the risk of PE recurrences is not influenced by the anatomic location of PE. |
format | Online Article Text |
id | pubmed-7845079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78450792021-02-02 Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation Fernández‐Capitán, Carmen Rodriguez Cobo, Ana Jiménez, David Madridano, Olga Ciammaichella, Maurizio Usandizaga, Esther Otero, Remedios Di Micco, Pierpaolo Moustafa, Farès Monreal, Manuel Res Pract Thromb Haemost Original Articles ‐ Thrombosis BACKGROUND: The optimal therapy of patients with acute subsegmental pulmonary embolism (PE) is controversial. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of symptomatic PE recurrences during anticoagulation in patients with subsegmental, segmental, or more central PEs. RESULTS: Among 15 963 patients with a first episode of symptomatic PE, 834 (5.2%) had subsegmental PE, 3797 (24%) segmental, and 11 332 (71%) more central PE. Most patients in all subgroups received initial therapy with low‐molecular‐weight heparin, and then most switched to vitamin K antagonists. Median duration of therapy was 179, 185, and 204 days, respectively. During anticoagulation, 183 patients developed PE recurrences, 131 developed deep vein thrombosis (DVT), 543 bled, and 1718 died (fatal PE, 135). The rate of PE recurrences was twofold higher in patients with subsegmental PE than in those with segmental (hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.16‐3.85) or more central PE (HR, 1.89; 95% CI, 1.12‐3.13). On multivariable analysis, patients with subsegmental PE had a higher risk for PE recurrences than those with central PE (adjusted HR, 1.75; 95% CI, 1.02‐3.03). After stratifying patients with subsegmental PE according to ultrasound imaging in the lower limbs, the rate of PE recurrences was similar in patients with DVT, in patients without DVT, and in those with no ultrasound imaging. CONCLUSIONS: Our study reveals that the risk for PE recurrences in patients with segmental PE is not lower than in those with more central PE, thus suggesting that the risk of PE recurrences is not influenced by the anatomic location of PE. John Wiley and Sons Inc. 2020-11-18 /pmc/articles/PMC7845079/ /pubmed/33537541 http://dx.doi.org/10.1002/rth2.12446 Text en © 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles ‐ Thrombosis Fernández‐Capitán, Carmen Rodriguez Cobo, Ana Jiménez, David Madridano, Olga Ciammaichella, Maurizio Usandizaga, Esther Otero, Remedios Di Micco, Pierpaolo Moustafa, Farès Monreal, Manuel Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation |
title | Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation |
title_full | Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation |
title_fullStr | Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation |
title_full_unstemmed | Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation |
title_short | Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation |
title_sort | symptomatic subsegmental versus more central pulmonary embolism: clinical outcomes during anticoagulation |
topic | Original Articles ‐ Thrombosis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845079/ https://www.ncbi.nlm.nih.gov/pubmed/33537541 http://dx.doi.org/10.1002/rth2.12446 |
work_keys_str_mv | AT fernandezcapitancarmen symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation AT rodriguezcoboana symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation AT jimenezdavid symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation AT madridanoolga symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation AT ciammaichellamaurizio symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation AT usandizagaesther symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation AT oteroremedios symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation AT dimiccopierpaolo symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation AT moustafafares symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation AT monrealmanuel symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation AT symptomaticsubsegmentalversusmorecentralpulmonaryembolismclinicaloutcomesduringanticoagulation |